Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review

Veltsista, Paraskevi D.; Oberacker, Eva; Ademaj, Adela; Corradini, Stefanie; Eckert, Franziska; Flörcken, Anne; Kaul, David; Линднер, Ларс; Issels, R. D.; Ott, Oliver J.; Pink, Daniel; Potkrajcic, Vlatko; Reichardt, Peter; Roohani, Siyer; Spałek, Mateusz; Riesterer, Oliver; Zips, Daniel; Ghadjar, Pirus

doi:10.1080/02656736.2023.2236337

Cited by 5 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This identified void in the literature underscores the pressing need for additional and targeted investigative endeavors in this specific domain of research. Addressing these gaps will not only contribute to a more holistic comprehension of STS but also offer valuable insights into optimizing treatment strategies in the era of ICIs ( 16 ). In light of the challenges posed by the rarity of STS, collaborative efforts in the form of multi-institutional studies and data pooling may prove instrumental in amassing a sufficiently large cohort for more robust analyses.…”

Section: Introductionmentioning

confidence: 99%

A novel nomogram and prognostic factor for metastatic soft tissue sarcoma survival

Han,

Li,

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundThis study represented the inaugural effort to develop predictive survival nomograms for metastatic soft tissue sarcoma (mSTS) patients in the era of immune checkpoint inhibitors.MethodFrom the Surveillance, Epidemiology, and End Results (SEER) program database, we extracted 3078 eligible patients with mSTS between 2016 and 2022. Kaplan-Meier survival analysis, univariate and multivariable Cox analyses, and univariate and multivariable logistic analyses were conducted. Subsequently, predictive nomograms were constructed. Clinical effectiveness was validated using the area under the curve (AUC), calibration curve, and decision curve analysis (DCA) methods.ResultsWe used the SEER database to include 3078 eligible patients with mSTS between 2016 and 2022. All the eligible patients were randomly allocated in a ratio of 6:4 and stratified into a training group (n = 1846) and a validation group (n = 1232). In the multivariate Cox analysis, age, race, marital status, pathological grade, histologic subtype, surgery, and chemotherapy were identified as independent prognostic factors. These factors were used to construct the nomogram to predict the 1-, 3-, and 5-year OS of mSTS patients. The C-index for the training cohort and the validation cohort was 0.722(95% confidence interval [CI]: 0.708–0.736), and 0.716(95% CI: 0.698–0.734), respectively. The calibration curves for 1-, 3-, and 5-year OS probability demonstrated excellent calibration between the predicted and the actual survival. The AUC values of the nomogram at 1-, 3-, and 5-year were 0.785, 0.767, and 0.757 in the training cohort, 0.773, 0.754, and 0.751 in the validation cohort, respectively. Furthermore, DCA indicated the favorable clinical utility of the nomogram in both cohorts. The risk stratification system was constructed using the established nomogram, which enhanced prediction accuracy, aided clinicians in identifying high-risk patients and informing treatment decisions.ConclusionThis study marked the inaugural effort in constructing predictive survival nomograms mSTS patients in the era of immune checkpoint inhibitors. The robustly constructed nomograms, alongside actual outcomes, offered valuable insights to inform follow-up management strategies.

show abstract

Section: Introductionmentioning

confidence: 99%